The regulatory state of nonalcoholic steatohepatitis and metabolism
- PMID: 33102795
- PMCID: PMC7576228
- DOI: 10.1002/edm2.113
The regulatory state of nonalcoholic steatohepatitis and metabolism
Conflict of interest statement
The authors declared no conflict of interest.
References
-
- www.clinicaltrials.gov. Accessed July 31, 2019.
-
- FDA . Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics. https://wwwfdagov/media/86377/download. Accessed July 31, 2019.
-
- FDA‐CDER .Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment: Guidance for Industry. https://wwwfdagov/media/119044/download . 2018. Accessed July 31, 2019.
-
- Docket Folder Summary: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment; FDA Draft Guidance for Industry. https://wwwregulationsgov/docket?D=FDA-2018-D-3632. Docket ID: FDA‐2018‐D‐3632. Accessed July 31, 2019.
-
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, MD). 2018;67(1):328‐357. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
